Audentes Therapeutics (NASDAQ:BOLD) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, The Fly reports.
BOLD has been the subject of several other reports. Mizuho reiterated a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, October 3rd. Guggenheim initiated coverage on Audentes Therapeutics in a research report on Tuesday, October 9th. They set a “neutral” rating for the company. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Tuesday, July 10th. Finally, BidaskClub downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $36.00.
Shares of NASDAQ:BOLD traded down $5.87 on Tuesday, hitting $23.69. 7,525 shares of the company’s stock were exchanged, compared to its average volume of 761,281. Audentes Therapeutics has a 12 month low of $24.51 and a 12 month high of $46.18. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -6.84 and a beta of 1.99.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.09). During the same period last year, the company posted ($0.88) earnings per share. On average, analysts forecast that Audentes Therapeutics will post -3.31 EPS for the current fiscal year.
In other Audentes Therapeutics news, Director Louis G. Lange sold 33,000 shares of Audentes Therapeutics stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $37.38, for a total value of $1,233,540.00. Following the transaction, the director now owns 365,999 shares in the company, valued at $13,681,042.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $36.88, for a total value of $368,800.00. Following the completion of the transaction, the vice president now owns 100 shares in the company, valued at approximately $3,688. The disclosure for this sale can be found here. Insiders sold 77,039 shares of company stock valued at $2,925,260 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Partner Investment Management L.P. purchased a new position in Audentes Therapeutics in the second quarter valued at about $162,000. Dynamic Technology Lab Private Ltd purchased a new position in Audentes Therapeutics in the second quarter valued at about $226,000. Quantitative Systematic Strategies LLC purchased a new position in Audentes Therapeutics in the second quarter valued at about $231,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Audentes Therapeutics in the second quarter valued at about $232,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Audentes Therapeutics in the first quarter valued at about $204,000. Institutional investors own 96.75% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Read More: What is Cost of Debt?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.